

## [Doxycycline](#)

Essential medicine status

Section:

[6. Anti-infective medicines](#) [6.5. Antiprotozoal medicines](#) [6.5.3. Antimalarial medicines](#) [6.5.3.3. Antimalarial medicines > Medicines for chemoprophylaxis in travellers](#)

ATC codes: [J01AA02](#)

EMLc

Indication

Malaria due to Plasmodium falciparum ICD11 code: [1F40](#)

INN

Doxycycline

Medicine type

Chemical agent

Antibiotic groups

[ACCESS](#)

List type

Core

Formulations

**Oral > Liquid:** 50 mg per 5 mL (calcium) ; 25 mg per 5 mL (monohydrate) powder for oral liquid

**Oral > Solid > dispersible tablet:** 100 mg (as monohydrate)

**Oral > Solid > dosage form:** 50 mg (as hyclate) ; 100 mg (as hyclate)

EML status history

First added in 2025 ([TRS 1064](#))

Sex

All

Age

Also recommended for children

Age restriction

> 8 years

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Doxycycline](#)

DrugBank

[Doxycycline](#)

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of doxycycline to the EML and EMLc for chemoprophylaxis of malaria due to P. falciparum in travelers in accordance with WHO guidance on international travel and health. Recommended formulations are the same as those recommended for doxycycline in Section 6.2.1 Access group antibiotics.